2025-08143RuleWallet

FDA Ranks DNA Cancer Detector as Safe Tool

Published Date: 5/9/2025

Rule

Summary

The FDA is officially putting the DNA-based test that checks for tiny amounts of leftover cancer cells in blood cancers into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while making it simpler for companies to get it to patients faster. The new rules started on May 9, 2025, and could speed up access to this important test without extra costs.

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

MRD Test Moved to Class II

The FDA officially classified the DNA-based test to measure minimal residual disease (MRD) in hematological malignancies as Class II (special controls), effective May 9, 2025, with the classification applicable on September 28, 2018. As a Class II device, it is subject to premarket notification under section 510(k) rather than automatic Class III premarket approval.

Enables Faster Market Entry for Future Tests

FDA stated that when a device is classified into Class II via the De Novo process, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application. This change was noted as a way to reduce regulatory burdens and enhance access to innovation.

Required Test Validation and Reporting Standards

The final order establishes special controls requiring detailed design verification and validation studies, labeling that lists the clinical hematopoietic malignancy, specimen type, and specific DNA regions detected, and requires the device output to include an estimated MRD frequency plus an uncertainty range (for example: "MRD = 1.2 x 10-5 [Range = 0.8 x 10-6 to 2.0 x 10-5]").

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register